| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Heart, Lung, and Blood Institute (NHLBI) Thalassemia Clinical Research Network |
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000623 |
Purpose
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
| Condition | Intervention |
|
Anemia, Cooley's Beta-Thalassemia Hematologic Diseases Thalassemia Osteoporosis Iron Overload Hypertension, Pulmonary |
Drug: Deferoxamine Drug: Deferiprone Drug: Arginine Drug: Sildenafil Drug: Decitabine |
| Genetics Home Reference related topics: | beta thalassemia pulmonary arterial hypertension |
| MedlinePlus related topics: | Anemia High Blood Pressure Osteoporosis Pulmonary Hypertension Thalassemia |
| Drug Information available for: | Sildenafil citrate Sildenafil 5-Aza-2'-deoxycytidine Arginine Deferoxamine Deferoxamine mesylate Arginine hydrochloride 1,2-Dimethyl-3-hydroxypyrid-4-one |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Thalassemia Clinical Research Network (TCRN) |
| Estimated Enrollment: | 1000 |
| Study Start Date: | July 2000 |
| Study Completion Date: | July 2006 |
 |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 1 Year to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please refer to specific studies for eligibility criteria.
Contacts and Locations| United States, California | |||||
| Children's Hospital Oakland | |||||
| Oakland, California, United States, 94609 | |||||
| United States, Massachusetts | |||||
| Children's Hospital | |||||
| Boston, Massachusetts, United States, 02115 | |||||
| United States, New York | |||||
| Weill Medical College of Cornell University | |||||
| New York, New York, United States, 10021 | |||||
| United States, Pennsylvania | |||||
| Children's Hospital of Philadelphia | |||||
| Philadelphia, Pennsylvania, United States, 19104 | |||||
| Canada, Ontario | |||||
| Toronto General Hospital | |||||
| Toronto, Ontario, Canada, M5G 2C4 | |||||
| National Heart, Lung, and Blood Institute (NHLBI) |
| Thalassemia Clinical Research Network |
| Principal Investigator: | Alan R. Cohen, MD | Children's Hospital of Philadelphia |
| Principal Investigator: | Patricia J. Giardina, MD | Weill Medical College of Cornell University |
| Principal Investigator: | Ellis J. Neufeld, MD, PhD | Children's Hospital |
| Principal Investigator: | Nancy F. Olivieri, MD | Toronto General Hospital |
| Principal Investigator: | Elliott P. Vichinsky, MD | Children's Hospital & Research Center Oakland |
| Principal Investigator: | Sonja McKinlay, PhD | New England Research Institutes, Inc. |
More Information
| Study ID Numbers: | 317, U01 HL65232, U01 HL65233, U01 HL65238, U01 HL65239, U01 HL65244, U01 HL65260 |
| First Received: | October 27, 1999 |
| Last Updated: | November 29, 2007 |
| ClinicalTrials.gov Identifier: | NCT00000623 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
|
